Cargando…
Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan
There are a few reports that focus on radiotherapy (RT) and cetuximab (CET) therapy exclusively for oral cancer. This retrospective study aimed to investigate the efficacy and safety of RT and CET therapy for locally advanced (LA) or recurrent/metastatic (R/M) oral squamous cell carcinoma (OSCC). Se...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002461/ https://www.ncbi.nlm.nih.gov/pubmed/36901553 http://dx.doi.org/10.3390/ijerph20054545 |
_version_ | 1784904395568185344 |
---|---|
author | Otsuru, Mitsunobu Yanamoto, Souichi Yamada, Shin-ichi Nakashiro, Kohichi Harazono, Yosuke Kohgo, Tomoyuki Nakamura, Moriyoshi Nomura, Takeshi Kasamatsu, Atsushi Tanaka, Susumu Kirita, Tadaaki Kioi, Mitomu Ogawa, Masaru Sasaki, Masashi Ota, Yoshihide Umeda, Masahiro |
author_facet | Otsuru, Mitsunobu Yanamoto, Souichi Yamada, Shin-ichi Nakashiro, Kohichi Harazono, Yosuke Kohgo, Tomoyuki Nakamura, Moriyoshi Nomura, Takeshi Kasamatsu, Atsushi Tanaka, Susumu Kirita, Tadaaki Kioi, Mitomu Ogawa, Masaru Sasaki, Masashi Ota, Yoshihide Umeda, Masahiro |
author_sort | Otsuru, Mitsunobu |
collection | PubMed |
description | There are a few reports that focus on radiotherapy (RT) and cetuximab (CET) therapy exclusively for oral cancer. This retrospective study aimed to investigate the efficacy and safety of RT and CET therapy for locally advanced (LA) or recurrent/metastatic (R/M) oral squamous cell carcinoma (OSCC). Seventy-nine patients from 13 hospitals who underwent RT and CET therapy for LA or R/M OSCC between January 2013 and May 2015 were enrolled in the study. Response, overall survival (OS), disease-specific survival (DSS), and adverse events were investigated. The completion rate was 62/79 (78.5%). The response rates in patients with LA and R/M OSCC were 69% and 37.8%, respectively. When only completed cases were examined, the response rates were 72.2% and 62.9%, respectively. The 1- and 2-year OS were 51.5% and 27.8%, respectively (median, 14 months), for patients with LA OSCC, and 41.5% and 11.9% (median, 10 months) for patients with R/M OSCC. The 1- and 2-year DSS were 61.8% and 33.4%, respectively (median, 17 months), for patients with LA OSCC, and 76.6% and 20.4% (median, 12 months) for patients with R/M OSCC. The most common adverse event was oral mucositis (60.8%), followed by dermatitis, acneiform rash, and paronychia. The completion rate was 85.7% in LA patients and 70.3% in R/M patients. The most common reason for noncompletion was an inadequate radiation dose due to worsening general conditions in R/M patients. Although the standard treatment for LA or R/M oral cancer is concomitant RT with high-dose cisplatin (CCRT) and the efficacy of RT and CET therapy for oral cancer is not considered to be as high as that for other head and neck cancers, it was thought that RT and CET therapy could be possible treatments for patients who cannot use high-dose cisplatin. |
format | Online Article Text |
id | pubmed-10002461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100024612023-03-11 Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan Otsuru, Mitsunobu Yanamoto, Souichi Yamada, Shin-ichi Nakashiro, Kohichi Harazono, Yosuke Kohgo, Tomoyuki Nakamura, Moriyoshi Nomura, Takeshi Kasamatsu, Atsushi Tanaka, Susumu Kirita, Tadaaki Kioi, Mitomu Ogawa, Masaru Sasaki, Masashi Ota, Yoshihide Umeda, Masahiro Int J Environ Res Public Health Article There are a few reports that focus on radiotherapy (RT) and cetuximab (CET) therapy exclusively for oral cancer. This retrospective study aimed to investigate the efficacy and safety of RT and CET therapy for locally advanced (LA) or recurrent/metastatic (R/M) oral squamous cell carcinoma (OSCC). Seventy-nine patients from 13 hospitals who underwent RT and CET therapy for LA or R/M OSCC between January 2013 and May 2015 were enrolled in the study. Response, overall survival (OS), disease-specific survival (DSS), and adverse events were investigated. The completion rate was 62/79 (78.5%). The response rates in patients with LA and R/M OSCC were 69% and 37.8%, respectively. When only completed cases were examined, the response rates were 72.2% and 62.9%, respectively. The 1- and 2-year OS were 51.5% and 27.8%, respectively (median, 14 months), for patients with LA OSCC, and 41.5% and 11.9% (median, 10 months) for patients with R/M OSCC. The 1- and 2-year DSS were 61.8% and 33.4%, respectively (median, 17 months), for patients with LA OSCC, and 76.6% and 20.4% (median, 12 months) for patients with R/M OSCC. The most common adverse event was oral mucositis (60.8%), followed by dermatitis, acneiform rash, and paronychia. The completion rate was 85.7% in LA patients and 70.3% in R/M patients. The most common reason for noncompletion was an inadequate radiation dose due to worsening general conditions in R/M patients. Although the standard treatment for LA or R/M oral cancer is concomitant RT with high-dose cisplatin (CCRT) and the efficacy of RT and CET therapy for oral cancer is not considered to be as high as that for other head and neck cancers, it was thought that RT and CET therapy could be possible treatments for patients who cannot use high-dose cisplatin. MDPI 2023-03-03 /pmc/articles/PMC10002461/ /pubmed/36901553 http://dx.doi.org/10.3390/ijerph20054545 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Otsuru, Mitsunobu Yanamoto, Souichi Yamada, Shin-ichi Nakashiro, Kohichi Harazono, Yosuke Kohgo, Tomoyuki Nakamura, Moriyoshi Nomura, Takeshi Kasamatsu, Atsushi Tanaka, Susumu Kirita, Tadaaki Kioi, Mitomu Ogawa, Masaru Sasaki, Masashi Ota, Yoshihide Umeda, Masahiro Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan |
title | Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan |
title_full | Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan |
title_fullStr | Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan |
title_full_unstemmed | Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan |
title_short | Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan |
title_sort | radiotherapy plus cetuximab for squamous cell carcinoma of the oral cavity: a multicenter retrospective study of 79 patients in japan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002461/ https://www.ncbi.nlm.nih.gov/pubmed/36901553 http://dx.doi.org/10.3390/ijerph20054545 |
work_keys_str_mv | AT otsurumitsunobu radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT yanamotosouichi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT yamadashinichi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT nakashirokohichi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT harazonoyosuke radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT kohgotomoyuki radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT nakamuramoriyoshi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT nomuratakeshi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT kasamatsuatsushi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT tanakasusumu radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT kiritatadaaki radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT kioimitomu radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT ogawamasaru radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT sasakimasashi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT otayoshihide radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan AT umedamasahiro radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan |